title: Topical tacrolimus: a new therapy for atopic dermatitis.
abstract: Atopic dermatitis is a common problem affecting up to 10 percent of all children. The mainstays of therapy have been oral antihistamines, topical emollients, topical doxepin, and topical corticosteroids. Side effects associated with higher potency topical corticosteroids have limited their use in children and for facial areas. Tacrolimus (Protopic) is an immunosuppressive agent typically used systemically in transplant patients. Used topically, it has been found to be effective in treating moderate to severe atopic dermatitis without causing the atrophy that might occur with prolonged use of topical corticosteroids. Tacrolimus works equally well in children and adults, with more than two thirds of both groups having an improvement of greater than 50 percent. Despite its potency, very little of the medication is systemically absorbed, and absorption decreases as the atopic dermatitis resolves. The main side effects are burning and itching, but these also decrease with improvement of the atopic dermatitis.
authors.affiliation: Family Practice Residency Program, Abington Memorial Hospital, Abington, Pennsylvania, USA.
authors.forename: John J
authors.initials: JJ
authors.lastname: Russell
mesh_terms: D000279:Administration, Cutaneous; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D016559:Tacrolimus